keyword
MENU ▼
Read by QxMD icon Read
search

Escitalopram

keyword
https://www.readbyqxmd.com/read/28730460/impact-of-safety-warnings-on-domperidone-prescribing-in-ireland
#1
M Teeling, M J MacAvin, K Bennett
AIM: This study aimed to investigate the impact of the 2014 safety warnings on use of domperidone, on subsequent prescribing patterns in Ireland. METHODS: The Irish HSE-PCRS pharmacy claims database was used to identify the study cohort (aged 18+), prescribed domperidone from Jan 2014 to Oct 2015. Dosage was available for each claim; concomitant prescription with the following drug classes was identified and calculated as a percentage of the total number of claims: anti-arrhythmics, macrolide antimicrobials and the selective serotonin receptor inhibitors (SSRIs) citalopram and escitalopram...
July 20, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28708853/selective-serotonin-reuptake-inhibitors-and-venlafaxine-in-pregnancy-changes-in-drug-disposition
#2
Andreas Austgulen Westin, Malin Brekke, Espen Molden, Eirik Skogvoll, Olav Spigset
BACKGROUND: Pregnancy may cause changes in drug disposition. The clinical consequences may be profound and even counterintuitive; in some cases pregnant women may need more than twice their usual drug dose in order to maintain therapeutic drug levels. For antidepressants, evidence on drug disposition in pregnancy is scarce. The aim of this study was to determine the effects of pregnancy on serum levels of selective serotonin reuptake inhibitors (SSRIs) and venlafaxine in a large and naturalistic patient material, in order to provide tentative dose recommendations for pregnant women...
2017: PloS One
https://www.readbyqxmd.com/read/28706455/escitalopram-a-selective-serotonin-reuptake-inhibitor-inhibits-voltage-dependent-k-channels-in-coronary-arterial-smooth-muscle-cells
#3
Han Sol Kim, Hongliang Li, Hye Won Kim, Sung Eun Shin, Mi Seon Seo, Jin Ryeol An, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Il-Whan Choi, Grace Choi, Dae-Sung Lee, Won Sun Park
We investigated the inhibitory effect of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on voltage-dependent K(+) (Kv) channels in freshly separated from rabbit coronary arterial smooth muscle cells. The application of escitalopram rapidly inhibited vascular Kv channels. Kv currents were progressively inhibited by an increase in the concentrations of escitalopram, suggesting that escitalopram inhibited vascular Kv currents in a concentration-dependent manner. The IC50 value and Hill coefficient for escitalopram-induced inhibition of Kv channels were 9...
July 2017: Korean Journal of Physiology & Pharmacology
https://www.readbyqxmd.com/read/28705766/patients-with-major-depressive-disorder-exhibit-reduced-reward-size-coding-in-the-striatum
#4
Masahiro Takamura, Yasumasa Okamoto, Go Okada, Shigeru Toki, Tetsuya Yamamoto, Naho Ichikawa, Asako Mori, Hideaki Minagawa, Yoshiyuki Takaishi, Yasutaka Fujii, Yoko Kaichi, Yuji Akiyama, Kazuo Awai, Shigeto Yamawaki
BACKGROUND: Anhedonia is a core symptom of major depressive disorder (MDD). While recent evidence suggests that reduced motivation for reward may be a core feature of anhedonia, the abnormalities in modulatory neural responses to variable reward amounts in MDD patients remain unclear. We investigated whether MDD patients' ability to represent variable-sized monetary rewards in the striatum is disrupted. METHODS: Twelve MDD patients and 12 healthy volunteers completed an assessment of psychometric status and participated in a functional magnetic resonance imaging (fMRI) task that involved the anticipation of financial reward (monetary incentive delay task)...
July 11, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28703951/secondary-prevention-of-chronic-ptsd-by-early-and-short-term-administration-of-escitalopram-a-prospective-randomized-placebo-controlled-double-blind-trial
#5
Joseph Zohar, Leah Fostick, Alzabeta Juven-Wetzler, Zeev Kaplan, Hadar Shalev, Gavriel Schreiber, Natalie Miroshnik, Arieh Y Shalev, Dan J Stein, Soraya Seedat, Sharain Suliman, Ehud Klein
OBJECTIVE: Prospective studies have not identified a viable pharmacologic strategy for secondary prevention of posttraumatic stress disorder (PTSD). The authors examined whether preventive intervention via early and short-term administration of a selective serotonin reuptake inhibitor (SSRI), within 1 month of exposure to a traumatic event (before diagnosis of PTSD could be made), may reduce the severity of PTSD symptoms according to DSM-IV at 13 months' follow-up. METHODS: Over 25,000 screening calls to patients referred to an emergency department for a traumatic event performed between June 2006 and December 2008 yielded 353 participants who were recruited within the month following a traumatic event ...
July 11, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28698115/interleukin-17-selectively-predicts-better-outcomes-with-bupropion-ssri-combination-novel-t-cell-biomarker-for-antidepressant-medication-selection
#6
Manish K Jha, Abu Minhajuddin, Bharathi Gadad, Tracy L Greer, Taryn L Mayes, Madhukar H Trivedi
BACKGROUND: Interleukin 17 (IL-17) is produced by highly inflammatory Th17 cells and has been implicated in pathophysiology of depression. IL-17 putatively disrupts the blood brain barrier and affects dopamine synthesis whereas dopamine has been shown to decrease Th17 cell-mediated immune response. Nevertheless, whether IL-17 can predict differential treatment outcome with antidepressants modulating dopaminergic transmission is unknown. METHODS: IL-17 and other T cell and non-T cell markers (Th1, Th2 and non-T cell markers) were measured with the Bioplex Pro™ human cytokine 27-plex kit in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants who provided baseline plasma and were treated with either bupropion plus escitalopram (bupropion-SSRI), escitalopram plus placebo (SSRI monotherapy), or venlafaxine plus mirtazapine (n=166)...
July 8, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28689006/interactions-between-pro-inflammatory-cytokines-and-statins-on-depression-in-patients-with-acute-coronary-syndrome
#7
REVIEW
Sung-Wan Kim, Hee-Ju Kang, Kyung-Yeol Bae, Il-Seon Shin, Young Joon Hong, Young-Keun Ahn, Myung Ho Jeong, Michael Berk, Jin-Sang Yoon, Jae-Min Kim
OBJECTIVE: Pro-inflammatory cytokines are associated with the development of depression and statins exert anti-inflammatory and antidepressant effects. The present study aimed to investigate associations between interleukin (IL)-6 and IL-18 and depression in patients with acute coronary syndrome (ACS) and potential interactions between statin use and pro-inflammatory cytokines on depression in this population. METHODS: We used pooled datasets from 1-year follow-up data from a 24-week randomized double-blind placebo-controlled trial (RCT) of escitalopram for treatment of depressive disorder and data from a naturalistic, prospective, observational cohort study in patients with ACS...
July 6, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28688279/synthesis-of-novel-5-aroylhydrazinocarbonyl-escitalopram-as-cholinesterase-inhibitors
#8
Mehr-Un Nisa, Munawar A Munawar, Amber Iqbal, Asrar Ahmed, Muhammad Ashraf, Qurra-Tul-Ann A Gardener, Misbahul A Khan
A novel series of 5-(aroylhydrazinocarbonyl)escitalopram (58-84) have been designed, synthesized and tested for their inhibitory potential against cholinesterases. 3-Chlorobenzoyl- (71) was found to be the most potent compound of this series having IC50 1.80 ± 0.11 μM for acetylcholinesterase (AChE) inhibition. For the butyrylcholinesterase (BChE) inhibition, 2-bromobenzoyl- (76) was the most active compound of the series with IC50 2.11 ± 0.31 μM. Structure-activity relationship illustrated that mild electron donating groups enhanced enzyme inhibition while electron withdrawing groups reduced the inhibition except o-NO2...
June 30, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28685616/cerebral-serotonin-release-correlates-with-11-c-az10419369-pet-measures-of-5-ht1b-receptor-binding-in-the-pig-brain
#9
Louise M Jørgensen, Pia Weikop, Claus Svarer, Ling Feng, Sune H Keller, Gitte M Knudsen
Positron emission tomography (PET) can, when used with appropriate radioligands, non-invasively capture temporal and spatial information about acute changes in brain neurotransmitter systems. We here evaluate the 5-HT1B receptor partial agonist PET radioligand, [(11)C]AZ10419369, for its sensitivity to detect changes in endogenous cerebral serotonin levels, as induced by different pharmacological challenges. To enable a direct translation of PET imaging data to changes in brain serotonin levels, we compared the [(11)C]AZ10419369 PET signal in the pig brain to simultaneous measurements of extracellular serotonin levels with microdialysis after various acute interventions (saline, escitalopram, fenfluramine)...
January 1, 2017: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/28673858/investigate-the-control-release-effect-of-ion-pair-in-the-development-of-escitalopram-transdermal-patch-using-ft-ir-spectroscopy-molecular-modeling-and-thermal-analysis
#10
Wei Wang, Tian Song, Xiaocao Wan, Chao Liu, Hanqing Zhao, Liang Fang
The aim of this study was to develop a controlled release drug-in-adhesive patch containing escitalopram (ESP) using ion-pair technique. Special attention was paid on the mechanism of how counter ion controlled the release of ESP. Five organic acids were chosen as the counter ions. Formulation factors including adhesive matrix, drug loading and permeation enhancers were investigated through in vitro experiments using rat skin and the optimized patch was evaluated using in vivo pharmacokinetic study. Drug-counter ion-PSA interactions were characterized by FT-IR, molecular modeling and DSC at molecular level...
June 30, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28666060/ssris-associated-with-decreased-risk-of-hepatocellular-carcinoma-a-population-based-case-control-study
#11
Hsiang-Lin Chan, Wei-Che Chiu, Vincent Chin-Hung Chen, Kuo-You Huang, Tsu-Nai Wang, Yena Lee, Roger S McIntyre, Tsai-Ching Hsu, Charles Tzu-Chi Lee, Bor-Show Tzang
BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin re-uptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. OBJECTIVE: he present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. METHODS: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59,859 cases with HCC and 285,124 matched controls...
June 30, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28663124/comparative-evaluation-of-vortioxetine-as-a-switch-therapy-in-patients-with-major-depressive-disorder
#12
Michael E Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L Jacobsen, Eduard Vieta
Switching antidepressant therapy is a recommended strategy for depressed patients who neither respond to nor tolerate an initial pharmacotherapy course. This paper reviews the efficacy and tolerability of switching to vortioxetine. All three published studies of patients with major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and versus sertraline, venlafaxine, bupropion, and citalopram in an indirect treatment comparison (ITC) from switch studies retrieved in a literature review...
June 26, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28657871/trial-of-electrical-direct-current-therapy-versus-escitalopram-for-depression
#13
RANDOMIZED CONTROLLED TRIAL
Andre R Brunoni, Adriano H Moffa, Bernardo Sampaio-Junior, Lucas Borrione, Marina L Moreno, Raquel A Fernandes, Beatriz P Veronezi, Barbara S Nogueira, Luana V M Aparicio, Lais B Razza, Renan Chamorro, Luara C Tort, Renerio Fraguas, Paulo A Lotufo, Wagner F Gattaz, Felipe Fregni, Isabela M Benseñor
BACKGROUND: We compared transcranial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depression. METHODS: In a single-center, double-blind, noninferiority trial involving adults with unipolar depression, we randomly assigned patients to receive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS plus oral placebo. The tDCS was administered in 30-minute, 2-mA prefrontal stimulation sessions for 15 consecutive weekdays, followed by 7 weekly treatments...
June 29, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28648553/escitalopram-plasma-levels-and-antidepressant-response
#14
Vincenzo Florio, Stefano Porcelli, Alois Saria, Alessandro Serretti, Andreas Conca
Major Depression Disorder (MDD) has a highly variable treatment response due to the large inter-individual variation in the pharmacokinetics and pharmacodynamics of drug treatments. In detail the correlation between plasma level and efficacy has been much debated. Among first-line drugs for MDD, one of the most used is escitalopram. In the present study we investigated the association between serum concentration of escitalopram (SCE) and antidepressant response (AR). 70 MDD patients treated with escitalopram monotherapy were recruited and followed for three months...
June 22, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28644875/estimation-of-the-optimal-dosing-regimen-of-escitalopram-in-dogs-a-dose-occupancy-study-with-11c-dasb
#15
Olivia Taylor, Nick Van Laeken, Ingeborgh Polis, Robrecht Dockx, Lise Vlerick, Andre Dobbeleir, Ingeborg Goethals, Jimmy Saunders, Nele Sadones, Chris Baeken, Filip De Vos, Kathelijne Peremans
Although the favourable characteristics of escitalopram as being the most selective serotonin reuptake inhibitor and having an increased therapeutic efficacy via binding on an additional allosteric binding site of the serotonin transporter, its dosing regimen has not yet been optimized for its use in dogs. This study aimed to estimate the optimal dosing frequency and the required dose for achieving 80% occupancy of the serotonin transporters in the basal ganglia. The dosing frequency was investigated by determining the elimination half-life after a four day oral pre-treatment period with 0...
2017: PloS One
https://www.readbyqxmd.com/read/28639557/effects-of-selective-seratonine-re-uptake-inhibitors-on-meniere-s-disease
#16
Olcay Kıroğlu, Özgür Sürmelioğlu, Mete Kıroğlu
OBJECTIVE: To evaluate the effects of selective serotonin re-uptake inhibitors (SSRIs) on Meniere's disease (MD) on patients who have both MD and generalized anxiety disorder. MATERIALS AND METHODS: All patients were evaluated with neurotologic examination, videonystagmography, audiological tests, and inner ear magnetic resonance imaging. Characteristic history and the evaluation of the patients' vertigo attacks during the attacks were the primary criteria for the diagnosis of MD...
June 21, 2017: Journal of International Advanced Otology
https://www.readbyqxmd.com/read/28635540/reduced-serum-vgf-levels-were-reversed-by-antidepressant-treatment-in-depressed-patients
#17
Haitang Jiang, Suzhen Chen, Na Lu, Yingying Yue, Yingying Yin, Yuqun Zhang, Wenhao Jiang, Jinfeng Liang, Yonggui Yuan
OBJECTIVES: VGF, a non-acronymic neuropeptide, is important in the pathogenesis of major depressive disorder (MDD) and in the functioning and efficacy of some antidepressant drugs. In this study we assessed whether serum VGF levels change in MDD patients and if antidepressant treatments can restore these changes. METHODS: We measured serum VGF concentrations using sandwich ELISA in drug-free MDD patients before treatment began (n = 26) and at 8 weeks after antidepressant treatment (n = 26) with escitalopram and duloxetine, two common antidepressants...
September 22, 2016: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28624596/repeated-co-treatment-with-antidepressants-and-risperidone-increases-bdnf-mrna-and-protein-levels-in-rats
#18
Zofia Rogóż, Katarzyna Kamińska, Patrycja Pańczyszyn-Trzewik, Magdalena Sowa-Kućma
BACKGROUND: Recently, several clinical studies have suggested a beneficial effect of a combination of antidepressants (ADs) with antipsychotic drugs in drug-resistant depression. Moreover, preclinical and clinical studies indicated a role of brain-derived neurotrophic factor (BDNF) in the pathology of depression, as well as in the mechanism of action of ADs. METHODS: In the present study, we investigated the effect of repeated administration of ADs, escitalopram, fluoxetine or mirtazapine and a low dose of risperidone (an atypical antipsychotic drug) given separately or in combination, on the mRNA and protein levels of BDNF or cAMP response element binding (p-CREB) in the hippocampus and frontal cortex of male Wistar rats...
March 4, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28621385/electroanalytical-determination-of-escitalopram-oxalate-using-nickel-nanoparticles-modified-carbon-paste-sensor
#19
Kamal Attia, A Mona Mohamed, M Amany Fekry
A sensitive voltammetric method was described for the determination of escitalopram oxalate based on electrocatalytic oxidation at nickel nanoparticles modified chloranil carbon paste sensor in Britton-Robinson buffer (pH range from 2 to 10). The modified electrode was characterized by scanning electron microscopy, electrochemical impedance and cyclic voltammetry. The investigation of electrochemical behavior of escitalopram oxalate was performed using cyclic voltammetry and differential pulse voltammetry. The anodic peak current showed a linear range from 1...
June 2017: Acta Chimica Slovenica
https://www.readbyqxmd.com/read/28616594/pattern-of-c-fos-expression-induced-by-tail-suspension-test-in-the-mouse-brain
#20
Kentaro Hiraoka, Keisuke Motomura, Satoru Yanagida, Ayako Ohashi, Nozomi Ishisaka-Furuno, Shigenobu Kanba
The tail suspension test (TST) has been widely used as a screening assay for antidepressant drugs. However, the neural substrates underlying the stress response and antidepressant-like effect during the TST remain largely unknown despite the prevalence of this test. In the present study, we used immunohistochemistry to examine alterations in c-Fos expression as a measure of neuronal activity in the mouse brain after acute administration of the antidepressant drugs nortriptyline or escitalopram (or saline as a control) with or without a subsequent TST session...
June 2017: Heliyon
keyword
keyword
7453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"